Verona Pharma plc VRNA
Set alert
106.91 0.00 0.00%
At close · Oct 7
106.91 Day range 106.91
106.81 52-week range 106.93
- YTD
- +130.21%
- 1 year
- +233.99%
- Open
- 106.91
- Prev close
- 106.91
- Mkt cap
- 72.68B
- Vol
- 1.87M
- Avg vol
- 1.46M
- EPS
- -0.99
- P/E
- 872.73
- Div yield
- 0.00%
More statistics
- Low
- 106.91
- High
- 106.91
- Forward P/E
- -381.82
- Beta
- 0.05
- Short ratio
- 1.56
- Inst. own
- 92.23%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 3, 2025
- 50-d avg
- 105.95
- 200-d avg
- 79.84
- 1y target
- 0.00
1Y chart
Events in this range
- Jul 1, 2025Rating: Wolfe Research · — → Outperform
- Jul 9, 2025Downgrade: Canaccord Genuity · Buy → Hold
- Jul 9, 2025Downgrade: Jefferies · Buy → Hold
- Jul 10, 2025Downgrade: BTIG · Buy → Neutral
- Jul 10, 2025Downgrade: Wells Fargo · Overweight → Equal-Weight
- Jul 14, 2025Downgrade: HC Wainwright & Co. · Buy → Neutral
Signals (41)
| Name | Date | Ago |
|---|---|---|
| RSI: Overbought | Oct 1, 2025 | 1 year ago |
| RSI: Overbought | Sep 25, 2025 | 1 year ago |
| RSI: Overbought | Sep 2, 2025 | 1 year ago |
| RSI: Overbought | Aug 20, 2025 | 1 year ago |
| RSI: Overbought | Aug 18, 2025 | 1 year ago |
| MACD: Sell Signal | Jul 23, 2025 | 1 year ago |
| MACD: Buy Signal | Jul 10, 2025 | 1 year ago |
| RSI: Overbought | Jul 9, 2025 | 1 year ago |
| MACD: Sell Signal | Jun 26, 2025 | 1 year ago |
| RSI: Overbought | May 30, 2025 | 1 year ago |
| MACD: Buy Signal | May 19, 2025 | 1 year ago |
| SMA: Bullish | May 12, 2025 | 1 year ago |
| SMA: Bearish | May 9, 2025 | 1 year ago |
| MACD: Sell Signal | May 9, 2025 | 1 year ago |
| RSI: Overbought | Apr 29, 2025 | 1 year ago |
| SMA: Bullish | Apr 23, 2025 | 1 year ago |
| MACD: Buy Signal | Apr 17, 2025 | 1 year ago |
| SMA: Bearish | Apr 1, 2025 | 1 year ago |
| MACD: Sell Signal | Mar 3, 2025 | 1 year ago |
| MACD: Buy Signal | Feb 28, 2025 | 1 year ago |
Newest 20 of 41.
Key statistics
- Market cap
- 9.09B
- Enterprise value
- 73.52B
- Trailing P/E
- 0.00
- Forward P/E
- -381.82
- PEG ratio
- 0.00
- Price / sales
- 40.98
- Price / book
- 33.04
- EPS (TTM)
- -1.04
- Beta
- 0.05
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- -36.63%
- Revenue (TTM)
- 221.67M
- Revenue growth
- 0.00%
- Free cash flow
- -57.39M
- Total cash
- 438.02M
- Total debt
- 244.37M
- Return on equity
- -36.36%
- Shares outstanding
- 84.98M
- Short % of float
- 2.44%
- 50-day average
- 105.95
- 200-day average
- 79.84
Analyst view
Consensus: hold
Hold
Price target (mean) 0.00
Ratings (0m) 6 0 buy · 6 hold · 0 sell
- Strong buy0
- Buy0
- Hold6
- Sell0
- Strong sell0
Next earnings
Nov 3, 2025
Expected Nov 3, 2025. Consensus EPS estimate 0.00.
Financials — quick view
VRNA Revenue — quarterly 103.14M
VRNA Net income — quarterly 11.92M
VRNA EPS — quarterly 0.16
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 3, 2025 | Sep 1, 2025 | 0.16 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jul 14, 2025 | HC Wainwright & Co. | down | Buy | Neutral |
| Jul 10, 2025 | Wells Fargo | down | Overweight | Equal-Weight |
| Jul 10, 2025 | BTIG | down | Buy | Neutral |
| Jul 9, 2025 | Jefferies | down | Buy | Hold |
| Jul 9, 2025 | Canaccord Genuity | down | Buy | Hold |
| Jul 1, 2025 | Wolfe Research | init | — | Outperform |
About Verona Pharma plc
Verona Pharma plc, a biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company offers Ohtuvayre, a dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that combines bronchodilator and non-steroidal anti-inflammatory effects for the maintenance treatment of chronic obstructive pulmonary disease, as well as cystic fibrosis and asthma. Verona Pharma plc was formerly known as Isis Resources plc and changed its name to Verona Pharma plc in September 2006. The company was incorporated in 2005 and is based in London, the United Kingdom. As of October 7, 2025, Verona Pharma plc operates as a subsidiary of Merck Sharp & Dohme LLC.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United Kingdom
- Website
- veronapharma.com
News
- The Year-End 2025 Biotech Rally And What It Means For 2026
- This Procter & Gamble Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday
- Verona Pharma, Rhythm Pharmaceuticals, AES And Other Big Stocks Moving Higher On Wednesday
- 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
- Why AES Shares Are Trading Higher By Over 10%; Here Are 20 Stocks Moving Premarket
- This Rollins Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
- Earnings Scheduled For April 29, 2025
- 10 Health Care Stocks With Whale Alerts In Today's Session
- Earnings Scheduled For February 27, 2025
- 5 Biotech Stocks With Key Catalysts This Week: Merck, Intellia, Verona, And More
Your note
Sign in to keep a note on VRNA — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ACKERMANN CHRISTINA M | Director | Conversion of Exercise of derivative security | Oct 6, 2025 | 0 |
| AUSTWICK MICHAEL | Director | Conversion of Exercise of derivative security | Oct 6, 2025 | 0 |
| DESCHAMPS LISA | Director | Conversion of Exercise of derivative security | Oct 6, 2025 | 0 |
| EDWARDS MARTIN | Director | Conversion of Exercise of derivative security | Oct 6, 2025 | 0 |
| HAHN MARK W | Chief Financial Officer | Conversion of Exercise of derivative security | Oct 6, 2025 | 0 |
| RICKARD KATHLEEN A | Officer | Conversion of Exercise of derivative security | Oct 6, 2025 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Janus Henderson Group PLC | 7.12% | 6,134,405 | 655.83M | Jun 29, 2025 |
| Perceptive Advisors Llc | 6.39% | 5,507,591 | 588.82M | Jun 29, 2025 |
| Darwin Global Management, Ltd. | 4.79% | 4,129,618 | 441.50M | Jun 29, 2025 |
| Frazier Life Sciences Management, L.P. | 3.93% | 3,383,950 | 361.78M | Jun 29, 2025 |
| RTW Investments LP | 3.54% | 3,051,878 | 326.28M | Jun 29, 2025 |
| Eventide Asset Management LLC | 3.15% | 2,715,324 | 290.30M | Jun 29, 2025 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| MUTUAL FUND SERIES TRUST-Eventide Gilead Fund | 2.19% | 1,889,627 | 202.02M | Jun 29, 2025 |
| T. Rowe Price Health Sciences Fund, Inc. | 1.57% | 1,357,044 | 145.08M | Jun 29, 2025 |
| JANUS INVESTMENT FUND-Janus Henderson Global Life Sciences Fund | 1.09% | 936,802 | 100.15M | Jun 29, 2025 |
| Manager Directed Portfolios-Hood River Small-Cap Growth Fund | 0.95% | 820,644 | 87.74M | Jul 30, 2025 |
| MUTUAL FUND SERIES TRUST-Eventide Healthcare & Life Sciences Fund | 0.94% | 809,112 | 86.50M | Jun 29, 2025 |
| Putnam Funds Trust-Putnam Small Cap Growth Fund | 0.85% | 734,132 | 78.49M | Jun 29, 2025 |